GlassScriptPhysician profile
Barry J Edison
NPI 1447283510
$2,938.76
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $174 · 2021: $209 · 2022: $292 · 2023: $845 · 2024: $631 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $472.35 | 2023 | M22 |
| Alcon Vision LLC | $460.17 | 2019-2025 | Eysuvis, Rocklatan, Tryptyr |
| Oyster Point Pharma, INC. | $253.29 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $214.94 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $146.48 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $146.20 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $143.98 | 2022-2025 | Xiidra, Miebo, Infuse |
| Kala Pharmaceuticals, INC. | $133.46 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $107.63 | 2024-2025 | Xdemvy |
| Abbvie INC. | $100.75 | 2022-2025 | Lumigan, Alphagan P |
| Allergan, INC. | $98.44 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $97.74 | 2019-2022 | |
| Amgen INC. | $97.12 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $77.26 | 2024-2025 | Tecnis Iol, Catalys System |
| Sight Sciences, INC. | $72.83 | 2021-2023 | Tearcare System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $70.00 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $59.23 | 2020-2021 | |
| Dompe US, INC. | $37.96 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $25.76 | 2022-2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $21.58 | 2023 | Acuvue |
| Thea Pharma INC. | $20.26 | 2023 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $17.21 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $15.46 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.92 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Edison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.